Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127561091 | 12756109 | 1 | I | 20160822 | 20160909 | 20160916 | 20160916 | EXP | DE-SA-2016SA167977 | AVENTIS | 11.00 | YR | C | M | Y | 32.00000 | KG | 20160916 | MD | DE | DE |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127561091 | 12756109 | 1 | PS | CLOFARABINE | CLOFARABINE | 1 | Unknown | U | UNKNOWN | 21673 | 30 | MG/M**2 | QD | ||||||
127561091 | 12756109 | 2 | SS | INOTUZUMAB OZOGAMICIN | INOTUZUMAB OZOGAMICIN | 1 | Intravenous (not otherwise specified) | U | 12-004948 | 0 | .8 | MG/M**2 | QD | ||||||
127561091 | 12756109 | 3 | SS | INOTUZUMAB OZOGAMICIN | INOTUZUMAB OZOGAMICIN | 1 | Intravenous (not otherwise specified) | U | 12-004948 | 0 | .5 | MG/M**2 | QD | ||||||
127561091 | 12756109 | 4 | SS | INOTUZUMAB OZOGAMICIN | INOTUZUMAB OZOGAMICIN | 1 | Intravenous (not otherwise specified) | U | 12-004948 | 0 | .5 | MG/M**2 | QD | ||||||
127561091 | 12756109 | 5 | SS | INOTUZUMAB OZOGAMICIN | INOTUZUMAB OZOGAMICIN | 1 | Intravenous (not otherwise specified) | U | 16-001116 | 0 | .5 | MG/M**2 | QD | ||||||
127561091 | 12756109 | 6 | SS | INOTUZUMAB OZOGAMICIN | INOTUZUMAB OZOGAMICIN | 1 | Intravenous (not otherwise specified) | U | 16-001116 | 0 | .5 | MG/M**2 | QD | ||||||
127561091 | 12756109 | 7 | SS | THIOTEPA. | THIOTEPA | 1 | Unknown | U | UNKNOWN | 0 | 8 | MG/KG | QD | ||||||
127561091 | 12756109 | 8 | SS | MELPHALAN | MELPHALAN | 1 | Unknown | U | UNKNOWN | 0 | 70 | MG/M**2 | QD | ||||||
127561091 | 12756109 | 9 | SS | ANTITHYMOCYTE IMMUNOGLOBULIN | THYMOCYTE IMMUNE GLOBULIN NOS | 1 | Unknown | U | UNKNOWN | 0 | |||||||||
127561091 | 12756109 | 10 | SS | ANTITHYMOCYTE IMMUNOGLOBULIN | THYMOCYTE IMMUNE GLOBULIN NOS | 1 | Unknown | U | UNKNOWN | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
127561091 | 12756109 | 1 | Bone marrow conditioning regimen |
127561091 | 12756109 | 7 | Bone marrow conditioning regimen |
127561091 | 12756109 | 8 | Bone marrow conditioning regimen |
127561091 | 12756109 | 9 | Bone marrow conditioning regimen |
127561091 | 12756109 | 10 | Prophylaxis against graft versus host disease |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
127561091 | 12756109 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
127561091 | 12756109 | Venoocclusive liver disease |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
127561091 | 12756109 | 1 | 20160802 | 20160806 | 0 | |
127561091 | 12756109 | 2 | 20160517 | 20160517 | 0 | |
127561091 | 12756109 | 3 | 20160525 | 20160525 | 0 | |
127561091 | 12756109 | 4 | 20160629 | 20160629 | 0 | |
127561091 | 12756109 | 5 | 20160706 | 20160706 | 0 | |
127561091 | 12756109 | 6 | 20160713 | 20160713 | 0 | |
127561091 | 12756109 | 7 | 20160807 | 20160807 | 0 | |
127561091 | 12756109 | 8 | 20160808 | 20160809 | 0 |